Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors

JAMA Oncol. 2020 Aug 1;6(8):1300-1301. doi: 10.1001/jamaoncol.2020.1932.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Humans
  • Melanoma* / drug therapy
  • Skin Neoplasms*

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab